| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:54 UTC |
|---|
| HMDB ID | HMDB0015227 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Fluvastatin |
|---|
| Description | Fluvastatin, also known as fluvas or fluindostatin, belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond. In humans, fluvastatin is involved in the fluvastatin action pathway. Fluvastatin is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Fluvastatin. |
|---|
| Structure | CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12 InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-(3S,5R)-Fluvastatin | ChEBI | | (3S,5R)-(-)-Fluvastatin | ChEBI | | (3S,5R,6E)-7-[3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | ChEBI | | Fluvas | Kegg | | (3S,5R,6E)-7-[3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate | Generator | | Fluindostatin | HMDB | | Fluvastatin sodium salt | HMDB | | Fluvastatin sodium | HMDB | | 7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate | HMDB | | Lescol | HMDB |
|
|---|
| Chemical Formula | C24H26FNO4 |
|---|
| Average Molecular Weight | 411.4659 |
|---|
| Monoisotopic Molecular Weight | 411.18458653 |
|---|
| IUPAC Name | (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
|---|
| Traditional Name | fluvastatin |
|---|
| CAS Registry Number | 93957-54-1 |
|---|
| SMILES | CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12 |
|---|
| InChI Identifier | InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m0/s1 |
|---|
| InChI Key | FJLGEFLZQAZZCD-JUFISIKESA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Pyrroles |
|---|
| Sub Class | Substituted pyrroles |
|---|
| Direct Parent | Phenylpyrroles |
|---|
| Alternative Parents | |
|---|
| Substituents | - 3-phenylpyrrole
- N-alkylindole
- Indole
- Indole or derivatives
- Medium-chain hydroxy acid
- Medium-chain fatty acid
- Beta-hydroxy acid
- Fluorobenzene
- Halobenzene
- Halogenated fatty acid
- Heterocyclic fatty acid
- Hydroxy fatty acid
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Hydroxy acid
- Fatty acyl
- Fatty acid
- Benzenoid
- Unsaturated fatty acid
- Heteroaromatic compound
- Secondary alcohol
- Carboxylic acid derivative
- Azacycle
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Organic nitrogen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organohalogen compound
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Carbonyl group
- Alcohol
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | - statin (synthetic) (CHEBI:5136 )
- (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (CHEBI:5136 )
|
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 194 - 197 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0044 g/L | Not Available | | LogP | 4.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.77 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.5486 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.28 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 48.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2690.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 266.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 196.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 179.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 197.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 631.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 513.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 72.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1183.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 540.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1420.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 363.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 428.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 217.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 124.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Fluvastatin,1TMS,isomer #1 | CC(C)N1C(/C=C/[C@@H](C[C@H](O)CC(=O)O)O[Si](C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3355.2 | Semi standard non polar | 33892256 | | Fluvastatin,1TMS,isomer #2 | CC(C)N1C(/C=C/[C@H](O)C[C@@H](CC(=O)O)O[Si](C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3307.7 | Semi standard non polar | 33892256 | | Fluvastatin,1TMS,isomer #3 | CC(C)N1C(/C=C/[C@H](O)C[C@H](O)CC(=O)O[Si](C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3299.7 | Semi standard non polar | 33892256 | | Fluvastatin,2TMS,isomer #1 | CC(C)N1C(/C=C/[C@@H](C[C@@H](CC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3324.9 | Semi standard non polar | 33892256 | | Fluvastatin,2TMS,isomer #2 | CC(C)N1C(/C=C/[C@@H](C[C@H](O)CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3310.5 | Semi standard non polar | 33892256 | | Fluvastatin,2TMS,isomer #3 | CC(C)N1C(/C=C/[C@H](O)C[C@@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3277.5 | Semi standard non polar | 33892256 | | Fluvastatin,3TMS,isomer #1 | CC(C)N1C(/C=C/[C@@H](C[C@@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3304.9 | Semi standard non polar | 33892256 | | Fluvastatin,1TBDMS,isomer #1 | CC(C)N1C(/C=C/[C@@H](C[C@H](O)CC(=O)O)O[Si](C)(C)C(C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3576.5 | Semi standard non polar | 33892256 | | Fluvastatin,1TBDMS,isomer #2 | CC(C)N1C(/C=C/[C@H](O)C[C@@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3522.8 | Semi standard non polar | 33892256 | | Fluvastatin,1TBDMS,isomer #3 | CC(C)N1C(/C=C/[C@H](O)C[C@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3530.9 | Semi standard non polar | 33892256 | | Fluvastatin,2TBDMS,isomer #1 | CC(C)N1C(/C=C/[C@@H](C[C@@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3714.5 | Semi standard non polar | 33892256 | | Fluvastatin,2TBDMS,isomer #2 | CC(C)N1C(/C=C/[C@@H](C[C@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3719.2 | Semi standard non polar | 33892256 | | Fluvastatin,2TBDMS,isomer #3 | CC(C)N1C(/C=C/[C@H](O)C[C@@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3669.9 | Semi standard non polar | 33892256 | | Fluvastatin,3TBDMS,isomer #1 | CC(C)N1C(/C=C/[C@@H](C[C@@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)=C(C2=CC=C(F)C=C2)C2=CC=CC=C21 | 3862.0 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Fluvastatin GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-6229000000-e7e9a4f18c77b8a3f328 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Fluvastatin GC-MS (3 TMS) - 70eV, Positive | splash10-03g0-9113255000-bbcec21c7d8450380f53 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Fluvastatin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Fluvastatin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvastatin 10V, Positive-QTOF | splash10-03xr-0082900000-af0bcdb98404aa7485cd | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvastatin 20V, Positive-QTOF | splash10-01b9-0090000000-fbe9d82e356a4c40ed62 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvastatin 40V, Positive-QTOF | splash10-00di-0290000000-4e6800fc8ed4bacd61c7 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvastatin 40V, Positive-QTOF | splash10-00di-0190000000-8d3aabcab51b7427b00c | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvastatin 20V, Positive-QTOF | splash10-01b9-0091000000-91a05c153cd55276cb1e | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fluvastatin 10V, Positive-QTOF | splash10-03xr-0064900000-6073674eb901911a6505 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 10V, Positive-QTOF | splash10-002f-0009100000-48400cafdfe7b1ae8e91 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 20V, Positive-QTOF | splash10-0fbc-2029000000-d4584fe54d4a4dee073e | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 40V, Positive-QTOF | splash10-0f79-8196000000-fb302f9ef42c788b0d34 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 10V, Negative-QTOF | splash10-03di-2009600000-fceb838edec69ac58798 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 20V, Negative-QTOF | splash10-0pi1-6109100000-0037246c25ef1a9001ac | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 40V, Negative-QTOF | splash10-0a4i-9124000000-574e6db0baf9d8f4ad3b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 10V, Negative-QTOF | splash10-03di-0007900000-94ec3a6470255ed0e510 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 20V, Negative-QTOF | splash10-0kmj-2009000000-f827f5fc9e84c0d8a8ee | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 40V, Negative-QTOF | splash10-01u3-5094000000-5b650479bc088483a8c2 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 10V, Positive-QTOF | splash10-03dl-0019500000-b32ac44df58c44fecd76 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 20V, Positive-QTOF | splash10-00ou-0039000000-533fcd1fe96ff3c27509 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluvastatin 40V, Positive-QTOF | splash10-0079-0091000000-fb70ed9366fe79b510e5 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|